Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP...(markets (U.S. and Europe). Helsinn Healt...)

Date:11/27/2008

markets (U.S. and Europe). Helsinn Healthcare's products are eventually out-licensed to its worldwide consolidated network of partners for distribution. Helsinn Healthcare's key products in the US are Aloxi(R) (palonosetron), distributed by Eisai Inc., USA, and Gelclair(R). The active pharmaceutical ingredients and the drug products are manufactured at Helsinn Healthcare's cGMP facilities and supplied worldwide to its customers. Helsinn Healthcare's chemical business focuses on the pharmaceutical chemical process development and manufacturing of advanced intermediates, Active Pharmaceutical Ingredients (APIs) and High Potency Active Ingredients (HPAIs) for both the Helsinn group and its outsourcing partners.

For more information about Helsinn Healthcare, please visit http://www.helsinn.com

About Zealand Pharma

Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. Zealand Pharma is one of the leaders within the peptide area, a growing market with significant drug development activities including treatment of metabolic and cardiovascular diseases. All of Zealand Pharma's products target diseases and symptoms of significant unmet clinical need and commercial potential.

Since 1999, Zealand Pharma's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out licensed to major pharmaceutical companies (Sanofi-Aventis, Wyeth and Helsinn Healthcare). All Zealand Pharma's compounds emerge from Zealand Pharma's own drug discovery.

AVE0010/ZP10, a pharmaceutical agent for the treatment of Type 2 Diabetes, has been out-licensed to Sanofi-Aventis, which is the world's third largest pharmaceutical corporation with a strong diabetes franchise. Phase III clinical trials were initiated in May 2008.

ZP120
'/>"/>

SOURCE Helsinn Healthcare SA Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
5. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
6. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast